董事会审计委员会工作细则 二Ο二五年九月 湖北亨迪药业股份有限公司 董事会审计委员会工作细则 第一条 为了明确湖北亨迪药业股份有限公司（以下简称"公司"）董事会 审计委员会（以下简称"委员会"）的职责，强化对公司经理层的监督，完善公 司治理机构，根据《公司法》《证券法》《上市公司独立董事管理办法》和《公 司章程》的规定，制订本细则。 第二条 审计委员会是董事会设立的专门工作机构，主要负责公司内、外部 审计的沟通、监督和核查工作，审核公司的财务信息及其披露，并行使《公司法》 规定的监事会的职权。 第三条 审计委员会成员须保证足够的时间和精力履行委员会的工作职责， 勤勉尽责，切实有效地监督公司的外部审计,指导公司内部审计工作，促进公司 建立有效的内部控制并提供真实、准确、完整的财务报告。 第四条 公司须为审计委员会提供必要的工作条件，配备专门人员或机构承 担审计委员会的工作联络、会议组织、材料准备和档案管理等日常工作。审计委 员会履行职责时，公司管理层及相关部门须给予配合。 第五条 委员会对董事会负责，其提案应提交董事会审查决定。 第二章 审计委员会的组织机构 湖北亨迪药业股份有限公司 董事会审计委员会工作细则 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in stock price within the next 6 to 12 months [3][22]. Core Views - The company has shown strong performance in its financial results, with a revenue of 822 million yuan in the first half of 2025, representing a year-on-year growth of 12.50%. The net profit attributable to shareholders reached 235 million yuan, up 24.55% year-on-year [5]. - The company is expected to continue benefiting from the growth of its peptide and small nucleic acid products, with a robust pipeline and ongoing capacity expansion projects [5]. - The financial forecasts for 2025-2027 indicate a revenue growth of 20.60%, 19.33%, and 19.25% respectively, with net profits expected to grow by 32.84%, 30.18%, and 28.95% [5]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 822 million yuan, with a net profit of 235 million yuan, reflecting a strong growth trajectory [5]. - The second quarter of 2025 saw a revenue of 420 million yuan, a 6.31% increase year-on-year, and a net profit of 115 million yuan, up 8.53% year-on-year [5]. Product Development - The company is actively expanding its product pipeline, with significant growth in peptide and small nucleic acid raw materials. The sales revenue for these products reached 510 million yuan in the first half of 2025, a 14.82% increase [5]. - The core product, Dydrogesterone tablets, has seen a sales revenue of 95.68 million yuan in the first half of 2025, with plans to penetrate the tertiary hospital market further [5]. Research and Development - The company has increased its R&D investment, with R&D expenses amounting to 71.8 million yuan in the first half of 2025, representing 8.74% of its revenue [5]. - The establishment of an AI small nucleic acid drug discovery laboratory in collaboration with East China Normal University is expected to open new growth avenues [5]. Profitability Metrics - The gross margin for the first half of 2025 was 60.11%, an increase of 3.09 percentage points year-on-year, while the net margin was 28.58%, up 2.77 percentage points [5]. - The company has maintained stable expense ratios, with sales and management expense ratios showing slight decreases [5].

线未来可期》2025-07-09 化学制药 美诺华（603538.SH） 证券研究报告/公司点评报告 2025 年 09 月 02 日 执业证书编号：S0740519040001 Email：zhujq@zts.com.cn | 基本状况 | | | --- | --- | | 总股本(百万股) | 219.83 | | 流通股本(百万股) | 215.39 | | 市价(元) | 26.78 | | 市值(百万元) | 5,887.01 | | 流通市值(百万元) | 5,768.23 | 股价与行业-市场走势对比 主业迎来拐点，创新布局打开成长空间 分季度看，2025Q2 公司实现营业收入 4.01 亿元，同比增长 16.15%，实现归母净利 润 0.28 亿元，同比增长 468.03%；实现扣非归母净利润 0.20 亿元，同比增长 +2213.81%。原料药业务底部夯实，制剂业务快速发展，创新业务布局打开成长空间， 公司有望在原料药+CDMO+制剂"全链条模式进入快速发展新篇章。 相关报告 1、《业绩预告靓丽，GLP-1 创新管 分业务：1）制剂：2025H1 收入 2.62 亿元，同比增长 111.0 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.89% on September 2, with Shuyatian leading the drop [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Ziji Shenzhou (688235) with a closing price of 324.85, up 8.28% [1] - Mengke Pharmaceutical (688373) at 8.26, up 8.12% [1] - Haichen Pharmaceutical (300584) at 68.49, up 7.22% [1] - Other significant performers included: - Beilu Pharmaceutical (300016) at 10.78, up 6.94% [1] - Warner Pharmaceutical (688799) at 56.73, up 5.56% [1] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.388 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.034 billion yuan [4] - Key stocks with notable capital flows included: - Baijishenzhou (688235) with a net inflow of 1.56 billion yuan from institutional investors [4] - Beilu Pharmaceutical (300016) with a net outflow of 41.53 million yuan from retail investors [4] ETF Information - The Huaxia Sci-Tech 100 ETF (product code: 588800) tracks the Shanghai Stock Exchange Sci-Tech 100 Index and has seen a 4.38% change over the last five days [6] - The current PE ratio stands at 231.01, with a recent reduction in shares by 65 million, indicating a net outflow of 782,000 yuan from institutional investors [6]

华海药业（600521.SH） 2025 上半年业绩有所波动，在研项目快速推进 2025 年 09 月 02 日 投资评级：买入（维持） 医药生物/化学制药 | 日期 | 2025/9/1 | | --- | --- | | 当前股价(元) | 26.59 | | 一年最高最低(元) | 26.59/13.49 | | 总市值(亿元) | 398.12 | | 流通市值(亿元) | 387.18 | | 总股本(亿股) | 14.97 | | 流通股本(亿股) | 14.56 | | 近 3 个月换手率(%) | 232.99 | 股价走势图 数据来源：聚源 -30% 0% 30% 60% 90% 2024-09 2025-01 2025-05 华海药业 沪深300 相关研究报告 《2024 年前三季度业绩快速增长，在 研项目进展顺利—公司信息更新报 告》-2024.11.3 《2024 上半年业绩快速增长，国内制 剂业务强劲增长—公司信息更新报 告》-2024.9.3 余汝意（分析师） 阮帅（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 ruanshuai@kysec.c ...

Core Viewpoint - The stock of Shuanglu Pharmaceutical has experienced fluctuations, with a recent decline of 2.04% and a total market capitalization of 7.89 billion yuan, indicating potential volatility in investor sentiment [1]. Financial Performance - For the first half of 2025, Shuanglu Pharmaceutical reported a revenue of 305 million yuan, a year-on-year decrease of 22.24%, while the net profit attributable to shareholders increased significantly by 309.08% to 121 million yuan [2]. - The company has distributed a total of 2.12 billion yuan in dividends since its A-share listing, with 277 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Shuanglu Pharmaceutical increased to 58,500, with an average of 14,564 circulating shares per person, a slight decrease of 1.33% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 8.69 million shares, an increase of 2.34 million shares from the previous period [3].

Group 1 - Zhonglun New Materials plans to reduce its shareholding by up to 4 million shares, accounting for 1% of the total share capital [1] - Haojiang Intelligent plans to reduce its shareholding by up to 1.5 million shares, accounting for 0.8364% of the total share capital [1] - Dekeli plans to reduce its shareholding by up to 474,180 shares, accounting for 3% of the total share capital [1][2] Group 2 - Fosun Pharma's subsidiary has received FDA approval for its HLX14 injection, intended for treating osteoporosis in postmenopausal women [3][4] - Shengtai Group plans to reduce its shareholding by up to 16.67 million shares, accounting for 3% of the total share capital [5] - Fangyuan Co. plans to reduce its shareholding by up to 15.3 million shares, accounting for 3% of the total share capital [6] Group 3 - Shenkai Co. completed a tender offer, resulting in 14.5655 million shares being accepted, giving the acquirer a 9.71% stake [8] - Guangdong Construction's 90MW solar-storage project in Tibet has achieved full capacity grid connection [9] - Kesi Technology plans to reduce its shareholding by up to 471,220 shares, accounting for 3% of the total share capital [9] Group 4 - Zhongtai Automobile's subsidiary faces forced execution, impacting its operational capacity [10] - Weima Agricultural Machinery plans to reduce its shareholding by up to 960,000 shares, accounting for 0.98% of the total share capital [10] - Tianqi Co. signed a strategic cooperation agreement with EVE Energy to enhance the lithium battery supply chain [11] Group 5 - Sudavige plans to acquire up to 51% of Changzhou Weipu Semiconductor Equipment Co. for a total valuation of up to 1 billion yuan [12] - Dengyun Co. plans to transfer 75% of its subsidiary's equity for 137 million yuan [13] - Sierte has received a notice of investigation from the China Securities Regulatory Commission for suspected information disclosure violations [14] Group 6 - Enjie Co. received a VAT refund of 188 million yuan for its subsidiary [15] - Jiama Clothing plans to reduce its shareholding by up to 366,000 shares, accounting for 0.28238% of the total share capital [16] - Xinong Co. plans to reduce its shareholding by up to 1.05 million shares, accounting for 0.6737% of the total share capital [17] Group 7 - Jiewate plans to jointly acquire 66.25% of Xinguang Haian for a total price of 418 million yuan [18] - Hubei Energy reported an increase in power generation by 22.05% year-on-year in August, with a total of 5.020 billion kWh generated [19][20] - Nasda signed a strategic cooperation agreement with Teld for collaboration in market and product innovation [21] Group 8 - Jinli Technology plans to reduce its shareholding by up to 978,200 shares, accounting for 0.56% of the total share capital [22][23]

Core Viewpoint - Pro Pharmaceutical's CDMO business is outperforming its API business, indicating a shift towards a new growth phase for the company as the API sector faces industry cycle challenges [1] Group 1: Business Performance - The API business is currently at the bottom of the industry cycle, leading to performance pressure year-on-year [1] - The CDMO business is entering a harvest period, which is expected to drive the company's performance growth [1]

2025.09. 02 本文字数：1575，阅读时长大约3分钟 封图 | AI生成 A股市场迎来9月"开门红"，9月1日，上证指数收于3875.53点，涨0.46%，深证成指收于12828.95 点，涨1.05%。 从资金流向数据看，9月第一个交易日，主力资金整体净流出，中小单资金积极入场，资金出现分 歧。未来哪些板块还有机会，大盘9月如何演绎？ 9月"开门红"，主力资金净流入医药领域 从资金流向的角度来看，资金出现分歧。东方财富Choice数据统计显示，主力资金整体呈现净流出 状态，9月1日主力净流入为-571.43亿元，主力净比达-2.08%，显示出主力资金在当日的操作上相 对谨慎。其中，超大单净流出244.45亿元，超大单净比-0.89%；大单净流出326.98亿元，大单净 比-1.19%。与之形成对比的是，中单和小单资金积极入场，中单净流入33.89亿元，中单净比 0.12%，小单净流入537.54亿元，小单净比1.95%，表明中小投资者对市场较为看好，积极参与交 易。 作者 | 第一财经 王媛丽 在板块资金流向方面，主力资金净流入的板块主要集中在医疗服务、生物制品和化学制药等医药相关 领域。医疗服务 ...

Group 1: Chemical Sector Performance - The chemical index showed a positive trend with all sub-sectors reporting gains, including a 1.92% increase in the chemical raw materials index, a 1% increase in the chemical machinery index, a 0.37% increase in the chemical pharmaceuticals index, and a 3.73% increase in the pesticide and fertilizer index [1] - The top five rising petrochemical products included normal butanol up 6.69%, TDI up 4.47%, calcium carbide up 4.44%, butadiene up 3.71%, and industrial naphthalene up 3.20% [1] - The five petrochemical products with the largest declines were liquid chlorine down 62.50%, dimethyl disulfide down 9.80%, normal propanol down 6.76%, dimethyl carbonate down 5.00%, and industrial-grade lithium carbonate down 4.63% [1] Group 2: Oil Sector Performance - The oil index experienced a decline, with the oil processing index down 1.29%, while the oil extraction index remained flat, and the oil trading index fell by 3.91% [1] - International crude oil prices showed a strong oscillation, with WTI settling at $64.01 per barrel, up 0.55% from August 22, and Brent settling at $68.12 per barrel, up 0.58% from August 22 [1] Group 3: Capital Market Performance of Chemical Companies - The top five rising listed chemical companies included Jianye Co. up 34.36%, Yunnan Energy Investment up 33.84%, Bai'ao Chemical up 21.93%, Aipu Co. up 20.11%, and *ST Yaxing up 17.61% [2] - The five listed chemical companies with the largest declines were Feilu Co. down 25.45%, Aladdin down 14.44%, Jinmei B shares down 14.35%, Zhun Oil down 13.00%, and Hengtai Aipu down 11.23% [2]